FUKOKU MUTUAL LIFE INSURANCE Co held its stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 800 shares of the life sciences company’s stock at the end of the 2nd quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Illumina were worth $139,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. increased its stake in Illumina by 2.6% during the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares during the period. Capital World Investors increased its stake in Illumina by 23.8% during the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the period. TIAA CREF Investment Management LLC increased its stake in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the period. Geode Capital Management LLC increased its stake in Illumina by 8.0% during the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after purchasing an additional 107,941 shares during the period. Finally, Winslow Capital Management LLC purchased a new stake in Illumina during the second quarter worth about $211,584,000. Institutional investors own 93.32% of the company’s stock.

A number of analysts have issued reports on ILMN shares. Deutsche Bank AG set a $175.00 price target on shares of Illumina and gave the stock a “hold” rating in a research note on Friday, July 28th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and boosted their price target for the stock from $170.00 to $215.00 in a research note on Monday, August 7th. Morgan Stanley reiterated an “underweight” rating and set a $122.00 price target (up from $115.00) on shares of Illumina in a research note on Monday, July 10th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research note on Wednesday, June 21st. Finally, Barclays PLC reiterated a “hold” rating and set a $150.00 price target on shares of Illumina in a research note on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. Illumina currently has an average rating of “Hold” and an average price target of $183.00.

In other news, Director Jay T. Flatley sold 22,540 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total value of $4,400,033.40. Following the completion of the sale, the director now directly owns 539,176 shares in the company, valued at approximately $105,252,546.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Omead Ostadan sold 1,672 shares of the business’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $172.73, for a total value of $288,804.56. Following the completion of the sale, the executive vice president now owns 26,242 shares of the company’s stock, valued at $4,532,780.66. The disclosure for this sale can be found here. Insiders have sold a total of 180,043 shares of company stock worth $35,255,073 over the last 90 days. 1.60% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/illumina-inc-ilmn-stake-held-by-fukoku-mutual-life-insurance-co/1610349.html.

Illumina, Inc. (NASDAQ:ILMN) traded down 0.29% during midday trading on Thursday, hitting $205.18. The stock had a trading volume of 63,370 shares. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34. The company has a 50-day moving average price of $201.87 and a 200-day moving average price of $183.93. The company has a market cap of $29.96 billion, a price-to-earnings ratio of 41.17 and a beta of 0.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company had revenue of $662.00 million for the quarter, compared to the consensus estimate of $642.38 million. During the same period in the previous year, the business earned $0.86 EPS. Illumina’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.